SFG
RVNC

Steward Financial Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Steward Financial Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$0 Buy
+4
New +$77 ﹤0.01% 1606

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Steward Financial Group's RVNC Position: Q3 2023 in Review

Steward Financial Group opened a new position in Revance Therapeutics, Inc. (RVNC) in Q3 2023: 4 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1606 among its holdings.

186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Steward Financial Group held 4 shares of Revance Therapeutics, Inc. worth $0 as of Q3 2023.
  • Revance Therapeutics, Inc. was a new Steward Financial Group position in Q3 2023.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #1606 holding.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.